The most significant achievements in gut microbiome science in 2018
27 Dec 2018by GMFH Editing Team
GMFH continue to cover the important progress made in our knowledge of the gut microbiota's impact on wellbeing and disease.
by GMFH Editing Team
GMFH continue to cover the important progress made in our knowledge of the gut microbiota's impact on wellbeing and disease.
The ultimate goal would be to create an "artificial stool", a consortium of commensal bacteria fermented and harvested in vitro,
by Paul Enck
A new systematic review and meta-analysis concludes that probiotics are associated with a lower risk of symptomatic C. difficile infection.
by Andreu Prados
A new review focuses on mechanisms leading to increased susceptibility to bacterial infection in the context of interactions between dietary transition metals,
by Andreu Prados
A new study has found that microbiota-accessible carbohydrate-utilizing bacteria and short-chain fatty acids generated during their fermentation prevent C. difficile infection perpetuation in mice.
by GMFH Editing Team
The scientific knowledge on probiotics is advancing very quickly—stay tuned for the second GMFH "best of probiotics" document.
A scientific committee chaired has taken care to put together a program that covers the most relevant issues in the field today.
by Kristina Campbell
In the new Gut Microbiota for Health “Clinical Minute” series, we get a scientific expert’s take on gut-microbiota-related questions to healthcare professionals.
Most mucosal surfaces of the human body contain an extremely complex ecosystem of microbial organisms. These resident microbes exist in a delicate balance with each other and the human host that is dictated by the specific local environmental factors of each host body site. In health, the many different species that make up the microbiota exist in homeostasis with the host immune system. A dysbiosis of the microbiota shifts the community, which may lead to disease.
by Andreu Prados
A recent study, led by Dr. Purna C. Kashyap from the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester (USA), has found that gut microbiota signatures may allow identification of patients with Clostridium difficile infection who will respond to initial treatment.